New Membership Benefit for 2022!

Posted on 22nd April 2022 by

As well as all the usual membership benefits we are are now offering advertising opportunities on our website and the best thing about it is, it is FREE!

Do you have job opportunities at your Hospice that you wished the wider Hospice at Home Community knew about? What about getting those events you are hosting into the public eye?

If the answer to any of these questions is yes or you can think of another opportunity you wish to advertise, then why not contact and advertise now.

Save the Date – NAHH Conference 2022.

Posted on 21st November 2019 by

Date: Tuesday 13 September 2022 (Virtual Event via Zoom).

NAHH are delighted to announce that their annual conference is back and the theme is ‘Taking what we have learnt into the future’.

This is a conference for everyone involved in end of life care… managers, commissioners, service leads but most of all the HCA’s who need our support and recognition of this vital and rewarding role.

More information on how to register and programme will be sent to you soon

If you are interested in attending or have any questions, please feel free to email


Important update from NHS England about the current availability of Levomepromazine

Posted on 18th April 2019 by

URGENT Levomepromazine 25mg/ml injection supply issue – information for Primary Care

Overview of Supply

  • Sanofi informed NHS England and DHSC on 5th April 2019 that they are going out of stock this week of levomepromazine 25mg/ml injection and new stock is expected to be available from the end of April.
  • The supply issue is due to a quality deviation experienced at their Italian factory and is not linked to EU exit.
  • The only other UK supplier, Wockhardt, have informed us that due to the unexpected increase in demand, they will also go out of stock of levomepromazine injection and their next delivery has been delayed with further stock expected at the end of April.
  • Wockhardt have confirmed the remaining levomepromazine 25mg/mL injection stock which is held at Alliance will be ring-fenced for primary care use only. Stock at Alliance is limited and will not last until the end of April.
  • Existing stocks are likely to be exhausted by end of this week and no new supplies are expected until end of April.
  • GPs, palliative care networks and community pharmacies should consider the following advice and work together during this period to ensure patients can be managed appropriately.

Alternative agents

  • UK Medicines Information with support of national clinical specialists have developed the following clinical information to help support the management of patients  who may be affected by this issue.
  • Please click here to view this guidance.
  • All the suppliers of the following medicines have  been made aware of this supply issue and have confirmed they can support an increase in demand should this be required.
  • Haloperidol 5mg/1ml solution for injection ampoules (DrugsRUs)
  • Midazolam 10mg/2ml solution for injection ampoules (Hameln, Accord, Roche)
  • Cyclizine 50mg/ml solution for injection ampoules (Advanz)
  • Metoclopramide 10mg/2ml solution for injection ampoules (Hameln, Ennogen)

Management Plan – GPs, Palliative Care Networks and Community Pharmacies to review and action immediately

  1. During the period of shortage, new patients should only be started on levomepromazine if other treatment options have been exhausted. This is to try to avoid disrupting existing treatment regimens where possible whilst acknowledging that for some new patients levomepromazine may be the only option available.
  2. Community pharmacies who require stock for existing patients should order Wockhardt stock from Alliance.
  3. Community pharmacies having difficulty obtaining stock should contact their local secondary care trusts as they have been asked to support primary care and hospices where possible, to understand if they have stock that can be made available to allow the continuation of treatment in existing patients.
  4. Some specialist importers have identified stock they can bring into the UK. Lead times vary between 7-21 days. If community pharmacies are considering ordering unlicensed imports, the community pharmacist will need to inform the prescribing doctor the product being supplied to the patients is an unlicensed product. Please consider placing orders now for 1-2 weeks of stock based on forecasted demand. We are currently aware that Clinigen, Waymade, Alium and Mawdsleys have sourced unlicensed supplies from abroad.
  5. Community pharmacies unable to obtain levomepromazine injection should liaise with the prescriber to discuss using an alternative product as outlined in the memo above.

NEW publication from the British Liver Trust

Posted on 22nd March 2019 by

British Liver Trust have a new publication called Thinking ahead: Planning for your future when you have advanced liver disease.

The aim of the publication, which was produced in collaboration with the UK’s leading experts in supportive and palliative care, is to raise awareness of the support services available to those living with advanced liver disease, and advise on how to access them.   There is a perception that palliative care particularly is available only in the last weeks or days of life, while in fact it may be accessed at any stage of a life-limiting illness to help with symptom management and / or the planning of future care.

The publication would be of interest to those living with advanced liver disease or caring for someone with advanced liver disease – click here for more information.


Posted on 6th March 2019 by

This year our Annual National Conference will be held at the Double Tree by Hilton, Coventry on the 11-12 June 2020 in Coventry.

The focus will be on developing, benchmarking and sustaining hospice at home services into the future and promoting ways of managing staff and organisational resilience.  This should help us to further influence commissioning agendas.

We have an exciting conference programme planned and the call for posters.  When open please do submit an abstract and remember to secure your Early Bird Member rate at the conference.  This rate is an added benefit of your membership renewal and enables us to give you a highly competitive rate for a residential event.

Improving Transitions for Young People Fund

Posted on 3rd January 2018 by

Together for Short Lives has launched a ground-breaking new funding programme to help address the cliff edge in care experienced by young adults in their transition from children’s to adult services. The programme is funding innovative projects that have the potential to transform the experience of young people with life-limiting conditions as they prepare for and move on to adult services.


Applications for Round Two of the Improving Transitions for Young People Fund will open in March 2018. The Together for Short Lives website will be updated with more details when they are available:


NAHH response to NICE call for evidence – End of Life Care services

Posted on 12th September 2016 by

The NAHH have sent a succinct report to NICE regarding End of Life Care services which includes citing several examples provided by member services in the last 12 months.

The report is available to download here

The NAHH thanks contributors and welcome any further responses and is aware that some member services will have submitted more detailed evidence on behalf of your Hospice at Home service through their organisation.


Article written by NAHH’s Kay Greene & Lesley Spencer published in European Journal of Palliative Care (EJPC)

Posted on 4th August 2016 by

The NAHH Trustees are delighted to share the news that a recent article written by Kay Greene and Lesley Spencer, has been published in the European Journal of Palliative Care (EJPC). The article outlines the NAHH strategy and explains who the NAHH is and what our Association’s goals are.

The article can be downloaded here -> 

This document is held under copyright by Hayward Group Ltd, publisher of the European Journal of Palliative Care. It may be downloaded for single academic use only. Reproduction for any other purpose is not allowed. For further information, please contact the editorial team by clicking here.